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Abstract NACP, the precursor protein of the non-amyloid L/
A4 protein (AL) component of Alzheimer’s disease (AD)
amyloid, also known as K-synuclein, was suggested to seed
amyloid plaque formation in AD by stimulating AL aggregation.
We have demonstrated that NACP experienced self-oligomer-
ization only in the presence of a modified AL fragment (AL25^
35) by using dicyclohexylcarbodiimide. This NACP oligomeriza-
tion, appearing as a discrete ladder on a Tricine SDS-PAGE,
was not observed with other AL peptides such as the reverse
peptide AL35^25 and AL1^40, indicating this process was
specific not only for the C-terminal peptide sequence of the AL
but also for its orientation. It might be, therefore, suggested that
the NACP self-oligomers formed only in the presence of a N-
terminally truncated AL peptide could act as a nucleation center
for plaque formation during AD development.
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Senile plaques are a neuropathological hallmark of Alz-
heimer’s disease (AD) [1^3]. The major constituent of this
proteinaceous amyloid deposit is a 39^43 amino acid amyloid
L/A4 protein (AL) posttranslationally derived from its much
longer precursor, APP. The AL peptide is, however, secreted
in a soluble form from various cell cultures under physiolog-
ical conditions and also found in cerebrospinal £uid (CSF) of
AD patients as well as normal controls [4^6]. It was, there-
fore, suggested that other factors associated with the plaque
or/and modi¢ed AL peptides could provide a nucleation cen-
ter to which soluble AL is accreted to form the deposit [7].
The senile plaque contains a peptide called non-AL compo-
nent of AD amyloid (NAC) as the second major constituent
which amounts to less than 10% to the AL [8]. This peptide is
proteolytically derived from its 140 amino acid precursor pro-
tein (NACP), also known as K-synuclein [9^11]. It has been
recently shown that the occurrence of a missense mutation on
this precursor gene which resulted in the substitution of threo-
nine for alanine at position 53 was closely related to early-
onset families of Parkinson’s disease [12]. A possible role of
NACP in amyloid plaque formation as a nucleation center has
emerged from a study of protein aggregation occurring be-
tween NACP and an AL peptide [13]. NACP interacted
with AL1^38 and formed an SDS-resistant 1:1 complex
through speci¢c hydrophobic interaction between the last 15
residues of the NAC region and AL25^35 which had been
shown to exhibit neurotoxicity [14]. At a molar ratio of
1:125 (NACP/AL), additional AL peptides formed thio£avin
S-stainable protein aggregates presumably by being attached
to the 1:1 NACP/AL nucleation center [13].
In this report, we demonstrate that NACP experiences self-
oligomerization only in the presence of an N-terminally trun-
cated AL fragment (residues 25^35) by using a zero-length
crosslinker of dicyclohexylcarbodiimide (DCCD). We suggest
that this NACP self-oligomer could participate in amyloid
plaque formation as a possible nucleation center.
2. Materials and methods
2.1. Preparation of NACP
Recombinant NACP was completely puri¢ed according to a proce-
dure previously described [15]. The recombinant plasmid containing
NACP was generously provided by Dr. R. Jakes. The NACP was kept
in 20 mM MES, pH 6.5 at a concentration of 1.2 mg/ml. A relatively
long-term storage would convert a small portion of the monomeric
NACP into an SDS-resistant dimeric species as others have already
pointed out [13].
2.2. NACP oligomerization in the presence of various AL fragments
NACP self-oligomerization was examined with either DCCD or
1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDAC) in the pres-
ence of various AL fragments such as AL1^40, AL25^35, and its
reverse peptide AL35^25. 100 pmol of NACP was preincubated with
the AL peptides at a constant molar ratio of 1:100 at 37‡C for 30 min
before the crosslinkers were added to 450 WM in a ¢nal volume of 20
Wl with 20 mM MES, pH 6.5. After the addition of either DCCD (a
stock of 4.5 mM) prepared in ethanol or EDAC in water, the reac-
tions were further incubated for an additional 1 h at the same temper-
ature and analyzed with the precast 10^20% Tricine gradient gels
(SDS-PAGE) from Novex according to a procedure provided by the
manufacturer. A discrete ladder formation due to NACP self-oligo-
merization was visualized on the gel with the silver staining procedure
of Morrissey [16].
2.3. NACP oligomerizations in the presence of various amounts of
AL25^35
The oligomerizations were induced in 20 mM MES, pH 6.5 at a
¢nal volume of 20 Wl in the presence of DCCD. All reactions were
carried out for 1 h with the reagent at 37‡C following 30 min of
preincubation between NACP and AL25^35. The amounts of AL25^
35 were varied to reach molar ratios between 0 to 500 with respect to
100 pmol of NACP. For the reactions with molar ratios higher than
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1:50 (NACP/AL25^35), the samples were centrifuged in a microfuge
at 13 000 rpm for 10 min. The resulting precipitates were solubilized
with the Tricine, SDS-PAGE sample bu¡er composed of 4% SDS,
12% glycerol, 0.0075% Coomassie blue G, and 0.0025% phenol red
in 0.45 M Tris-HCl, pH 8.45 and analyzed with a precast 10^20%
Tricine gradient gel from Novex.
2.4. Competition of NAC during the AL25^35 induced NACP
oligomerization
The NACP oligomerizations were observed with 450 WM DCCD in
the presence of 5 nmol of AL25^35 and various amounts of NAC to
give molar ratios of 0, 1, 3, 5, 10, 30, 50, and 100 with respect to 0.1
nmol of NACP. The reactions were done and analyzed with the Tri-
cine gradient gel as mentioned above.
3. Results and discussion
As has been indicated by several independent studies,
NACP can exist in a dimeric form [13,15,17]. In order to
examine the dimeric or possible self-oligomeric forms of
NACP, we introduced zero-length crosslinkers of either the
water-insoluble DCCD or EDAC as a water-soluble reagent
since we expected that their accessibilities to the protein would
be dependent upon their chemical natures.
Surprisingly, NACP self-oligomerization was detected as a
discrete ladder formation on a 10^20% Tricine, SDS-PAGE
only in the presence of AL25^35 with DCCD (Fig. 1). When
the puri¢ed NACP was analyzed with the gel and visualized
with the silver staining procedure, a small fraction of the
protein appeared as a dimeric species (Fig. 1A). When the
protein was reacted with 450 WM DCCD for 1 h at 37‡C,
the NACP band was split into a broad doublet with a slightly
increased level of the dimeric form (Fig. 1B, lane 1). The
doublet consisted of a band with the same mobility as
NACP and another fast-mobile species which might be due
to intramolecular crosslinking of the protein. When this reac-
tion was carried out in the presence of an N-terminally trun-
cated AL peptide, AL25^35, a distinct ladder due to NACP
self-oligomerization was clearly visualized at a molar ratio of
1:100 (NACP/AL25^35) (Fig. 1B, lane 2). Intriguingly, how-
ever, this ladder was not formed in the presence of the reverse
sequence of the modi¢ed peptide, AL35^25, at the same molar
ratio (Fig. 1B, lane 3). The ladder was not observed even in
the presence of various amounts of this reverse peptide (data
not shown). This fact clearly indicates that the NACP self-
oligomerization was dependent not only upon the amino acid
sequence of AL25^35 but upon its orientation as well. When
AL1^40 was used to determine its involvement in the oligo-
merization, it was not successful, indicating that additional
parts of the peptide certainly interfered with the optimal in-
teractions among NACP mediated via AL25^35. On the other
hand, however, AL1^40 was self-oligomerized independently
of NACP and non-speci¢cally aggregated by itself (Fig. 1B,
lane 4). This was con¢rmed by the smeared appearance of the
peptide on the gel. When the amount of AL1^40 was in-
creased to the higher concentration of 1 mM, NACP oligo-
merizations were still not observed. It is, therefore, pertinent
to consider that an aggregate formed only within the AL
peptides experiences a totally di¡erent mechanism of protein
aggregation from that produced in the presence of NACP. It
could be speculated that the presence of a large amount of
physiologically soluble AL1^40 in the senile plaque might be
caused by a secondary process of accretion following the pri-
mary formation of NACP self-oligomers induced by substan-
ces like AL25^35 via very tight associations with NACP.
When other AL peptide fragments such as AL1^28, AL31^
35, and AL1^42 were examined in terms of their abilities to
induce the oligomers, however, none of them were e¡ective
(data not shown). In addition, when the water-soluble carbo-
diimide (EDAC) was used instead of DCCD, there were no
NACP oligomerizations observed in the presence of any pep-
tides tested (Fig. 1C). This fact indicates that hydrophobic
region(s) generated upon NACP and AL25^35 association
must be located adjacent to each other, which can be accessed
and crosslinked by the relatively hydrophobic carbodiimide,
DCCD.
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Fig. 1. NACP and its self-oligomerization in the presence of AL-derived peptides accessed with the zero-length crosslinkers DCCD (B) and
EDAC (C). A: The completely puri¢ed recombinant NACP (100 pmol) was analyzed on the gel. B: DCCD treatment of NACP (100 pmol) in
the presence of various AL fragments at a constant molar ratio of 1:100 (NACP/AL peptides). Self-oligomerization of NACP was observed
with 450 WM DCCD only in the presence of 10 nmol of AL25^35 (lane 2). Lane 1 contains 100 pmol of NACP reacted with DCCD in the ab-
sence of AL peptides. Lane 3 is NACP in the presence of the reverse sequence of AL25^35, AL35^25. Lane 4 exhibits the e¡ect of AL1^40 on
NACP. C: EDAC treatment to examine the e¡ects of AL peptides on NACP in the same reaction conditions as B. Lane 1, NACP reacted
with 450 WM EDAC in the absence of AL peptides; lane 2, NACP with AL25^35; lane 3, NACP with AL35^25; lane 4, NACP with AL1^40.
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Changes in the NACP oligomerization in the presence of
various amounts of AL25^35 were studied to demonstrate the
oligomer’s possible role as a nucleation center during amyloid
development. Firstly, the oligomerization began to be gener-
ated even at a 1:1 molar ratio between the two molecules (Fig.
2A), indicating that the NACP self-oligomerization can be
induced even in the presence of a small amount of AL25^35
with high a⁄nity. This can rationalize our approach to inves-
tigate the e¡ects of AL25^35 on NACP rather than observing
NACP-induced phenomena such as AL25^35 aggregation.
Secondly, the extents of oligomerization became biphasic as
AL25^35 concentrations were increased (Fig. 2). The oligo-
merization was enhanced until the molar ratio between
NACP and AL25^35 reached between 1:30 and 1:50 (Fig.
2A) and decreased thereafter (Fig. 2B). Interestingly, this
disappearance of the oligomers did not augment the NACP
band. In addition, these oligomers were found exclusively in
the precipitates following the oligomerization reactions.
Hence, these facts possibly indicate that SDS-PAGE-im-
permeable protein aggregates were formed at high AL25^35
concentrations (Fig. 2B).
Competitive e¡ects of NAC on the AL25^35 interaction
with NACP were investigated to con¢rm whether the hydro-
phobic NAC region in NACP is responsible for the AL25^35
mediated oligomerization (Fig. 3). NAC protected the oligo-
merization from a molar ratio of 1:30 between NACP and
NAC, indicating that the interactions between AL25^35 and
the NAC region could be critical during this process. How-
ever, the lack of complete protection even in the presence of
100-fold molar excess of NAC to its precursor cannot exclude
the possibility that additional sequences of NACP besides the
hydrophobic NAC region may have certain functions during
the oligomerization [17]. This result also implies that protein
aggregations mediated by an amyloidogenic NAC and the
NACP self-oligomerization should be di¡erentiated from
each other in terms of their underlying biochemical mecha-
nisms [18,19].
It was originally demonstrated that NAC was immunolog-
ically found not only in mature neuritic plaques but also in
di¡use, primitive amyloid deposits [8]. The NAC is an intrin-
sic constituent of AD amyloid because its isolation required a
series of extensive treatments such as sonication in SDS bu¡-
er, CNBr cleavage in 70% formic acid, and Achromobacter
lyticus protease I digestion in 5 M urea and its immunological
localization was observed electron microscopically unlike oth-
er amyloid-associated factors. Unfortunately, however, the
de¢nitive structures of the N- and C-termini of NAC in the
plaque could not be identi¢ed because of the extensive chem-
ical and proteolytic digestions. In fact, the N-terminal portion
of NAC in the precursor contains 11 lysine residues which can
be cleaved by the protease out of 60 amino acid residues. In
addition, the C-terminal acidic region of NACP with three
lysines and one methionine, a target for CNBr cleavage, might
be di⁄cult to thoroughly analyze with the C4 reversed-phase
HPLC because of its hydrophilic property [8]. Therefore, the
actual involvement of NACP in plaque formation has never
been completely understood. Based on these facts together
with our observations, we suggest that the NACP self-oligo-
mers generated in the presence of a modi¢ed AL peptide like
AL25^35 could be a reasonable candidate to seed plaque for-
mation although the actual presence of any AL peptide frag-
ments in physiological conditions, which are capable of caus-
ing NACP oligomerization, needs to be examined. Moreover,
in order to unravel the signi¢cant role of NACP self-oligo-
mers, it should be examined where the oligomers are initially
generated and whether they are susceptible to various intra-
cellular or extracellular proteases. Although the exact nature
of NACP during senile plaque formation in AD remains to be
determined, the molecule and the phenomenon of self-oligo-
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Fig. 2. NACP self-oligomerization in the presence of various
amounts of AL25^35. All reactions were carried out in 20 mM
MES, pH 6.5 at 37‡C for 1 h with DCCD following 30 min of pre-
incubation at the same temperature between NACP and the peptide
prior to the addition of the crosslinker. Stock solutions of NACP
and AL25^35 were prepared in 20 mM MES, pH 6.5 at ¢nal con-
centrations of 1.2 mg/ml and 1 nM, respectively. A: The oligomeri-
zation was induced with 225 WM DCCD in a total volume of 20 Wl
in the presence of various amounts of the AL25^35 in molar ratios
of 0, 1, 3, 5, 10, 30, and 50^100 pmol of NACP (lanes 2^8). Lane 1
shows NACP silver-stained in the absence of DCCD. B: The same
reactions were performed with 450 WM DCCD in a total volume of
60 Wl with increasing amounts of the AL peptide of 5, 10, 30, 40,
and 50 nmol (lanes 1^5) in the presence of 100 pmol of NACP,
which led to the ratios (AL25^35/NACP) of 50, 100, 200, 300, and
500 as indicated. After the reactions were completed, the samples
were centrifuged in a microfuge at 13 000 rpm for 10 min. The re-
sulting precipitates were solubilized with the Tricine, SDS-PAGE
sample bu¡er.
Fig. 3. NAC e¡ect on NACP self-oligomerization in the presence of
AL25^35. The amounts of NAC were 0, 0.1, 0.3, 0.5, 1, 3, 5, and
10 nmol (lanes 1^8) with respect to 0.1 and 5 nmol of NACP and
AL25^35, respectively. The reactions were done with 450 WM of
DCCD at 37‡C for 1 h in a total volume of 20 Wl following 30 min
of preincubation among NACP, AL25^35, and NAC. NAC stock
was prepared at 1 nM in 20 mM MES, pH 6.5. The Tricine gra-
dient gel (10^20%) from Novex was used and the oligomers were
visualized with silver stain.
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merization are certainly valuable tools to approach the abnor-
mal protein depositions. Finally, we expect that this visual-
ization method of the NACP oligomers with DCCD in the
presence of AL25^35 can provide a powerful assay system not
only to approach the structure-function relationship of NACP
during amyloid formation but also to evaluate various phys-
iological or pharmacological e¡ectors with respect to develop-
ing therapeutic or preventive strategies for both Alzheimer’s
and Parkinson’s diseases.
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